|
1
|
Perumpail BJ, Khan MA, Yoo ER, Cholankeril
G, Kim D and Ahmed A: Clinical epidemiology and disease burden of
nonalcoholic fatty liver disease. World J Gastroenterol.
23:8263–8276. 2017.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Forbes S, Taylor-Robinson SD, Patel N,
Allan P, Walker BR and Johnston DG: Increased prevalence of
non-alcoholic fatty liver disease in European women with a history
of gestational diabetes. Diabetologia. 54:641–647. 2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Chang Y, Jung HS, Yun KE, Cho J, Cho YK
and Ryu S: Cohort study of non-alcoholic fatty liver disease, NAFLD
fibrosis score, and the risk of incident diabetes in a Korean
population. Am J Gastroenterol. 108:1861–1868. 2013.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Yamada T, Fukatsu M, Suzuki S, Wada T,
Yoshida T and Joh T: Fatty liver predicts impaired fasting glucose
and type 2 diabetes mellitus in Japanese undergoing a health
checkup. J Gastroenterol Hepatol. 25:352–356. 2010.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Cohen JC, Horton JD and Hobbs HH: Human
fatty liver disease: Old questions and new insights. Science.
332:1519–1523. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Fabbrini E, Sullivan S and Klein S:
Obesity and nonalcoholic fatty liver disease: Biochemical,
metabolic, and clinical implications. Hepatology. 51:679–689.
2010.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Sreenivasa Baba C, Alexander G, Kalyani B,
Pandey R, Rastogi S, Pandey A and Choudhuri G: Effect of exercise
and dietary modification on serum aminotransferase levels in
patients with nonalcoholic steatohepatitis. J Gastroenterol
Hepatol. 21:191–198. 2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kim WS, Lee YS, Cha SH, Jeong HW, Choe SS,
Lee MR, Oh GT, Park HS, Lee KU, Lane MD, et al: Berberine improves
lipid dysregulation in obesity by controlling central and
peripheral AMPK activity. Am J Physiol Endocrinol Metab.
296:E812–E819. 2009.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Qian S, Ma L, Peng S, Xu Y, Wu K, Shen S,
Zhang X, Sun Y and Ye J: ATP reduces mitochondrial MECR protein in
liver of diet-induced obese mice in mechanism of insulin
resistance. Biosci Rep. 40(40)2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Qin S, Tang H, Li W, Gong Y, Li S, Huang
J, Fang Y, Yuan W, Liu Y, Wang S, et al: AMPK and its activator
berberine in the treatment of neurodegenerative diseases. Curr
Pharm Des. 26:5054–5066. 2020.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Li Q, Zhao C, Zhang Y, Du H, Xu T, Xu X,
Zhang J, Kuang T, Lai X, Fan G, et al: 1H NMR-based metabolomics
coupled with molecular docking reveal the anti-diabetic effects and
potential active components of berberis vernae on type 2 diabetic
rats. Front Pharmacol. 11(932)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Xing LJ, Zhang L, Liu T, Hua YQ, Zheng PY
and Ji G: Berberine reducing insulin resistance by up-regulating
IRS-2 mRNA expression in nonalcoholic fatty liver disease (NAFLD)
rat liver. Eur J Pharmacol. 668:467–471. 2011.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Yang QH, Hu SP, Zhang YP, Xie WN, Li N, Ji
GY, Qiao NL, Lin XF, Chen TY and Liu HT: Effect of berberine on
expressions of uncoupling protein-2 mRNA and protein in hepatic
tissue of non-alcoholic fatty liver disease in rats. Chin J Integr
Med. 17:205–211. 2011.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Li S, Xu Y, Guo W, Chen F, Zhang C, Tan
HY, Wang N and Feng Y: The impacts of herbal medicines and natural
products on regulating the hepatic lipid metabolism. Front
Pharmacol. 11(351)2020.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Liu R, Wu K, Li Y, Sun R and Li X: Human
antigen R: A potential therapeutic target for liver diseases.
Pharmacol Res. 155(104684)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Li CH, Tang SC, Wong CH, Wang Y, Jiang JD
and Chen Y: Berberine induces miR-373 expression in hepatocytes to
inactivate hepatic steatosis associated AKT-S6 kinase pathway. Eur
J Pharmacol. 825:107–118. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Pan X and Hussain MM: Diurnal regulation
of microsomal triglyceride transfer protein and plasma lipid
levels. J Biol Chem. 282:24707–24719. 2007.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yuan F, Wang H, Tian Y, Li Q, He L, Li N
and Liu Z: Fish oil alleviated high-fat diet-induced non-alcoholic
fatty liver disease via regulating hepatic lipids metabolism and
metaflammation: A transcriptomic study. Lipids Health Dis.
15(20)2016.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Lu Z, He B, Chen Z, Yan M and Wu L:
Anti-inflammatory activity of berberine in non-alcoholic fatty
liver disease via the Angptl2 pathway. BMC Immunol.
21(28)2020.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Mai W, Xu Y, Xu J, Zhao D, Ye L, Yu G,
Wang Z, Lu Q, Lin J, Yang T, et al: Berberine inhibits nod-like
receptor family pyrin domain containing 3 inflammasome activation
and pyroptosis in nonalcoholic steatohepatitis via the ROS/TXNIP
axis. Front Pharmacol. 11(185)2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Zhu X, Bian H, Wang L, Sun X, Xu X, Yan H,
Xia M, Chang X, Lu Y, Li Y, et al: Berberine attenuates
nonalcoholic hepatic steatosis through the AMPK-SREBP-1c-SCD1
pathway. Free Radic Biol Med. 141:192–204. 2019.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Bedossa P: Pathology of non-alcoholic
fatty liver disease. Liver Int. 37 (Suppl 1):85–89. 2017.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Kojima S, Watanabe N, Numata M, Ogawa T
and Matsuzaki S: Increase in the prevalence of fatty liver in Japan
over the past 12 years: Analysis of clinical background. J
Gastroenterol. 38:954–961. 2003.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Adams LA, Angulo P and Lindor KD:
Nonalcoholic fatty liver disease. CMAJ. 172:899–905.
2005.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Bedogni G, Miglioli L, Masutti F,
Tiribelli C, Marchesini G and Bellentani S: Prevalence of and risk
factors for nonalcoholic fatty liver disease: The Dionysos
nutrition and liver study. Hepatology. 42:44–52. 2005.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Browning JD, Szczepaniak LS, Dobbins R,
Nuremberg P, Horton JD, Cohen JC, Grundy SM and Hobbs HH:
Prevalence of hepatic steatosis in an urban population in the
United States: Impact of ethnicity. Hepatology. 40:1387–1395.
2004.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Day CP and James OF: Steatohepatitis: A
tale of two ‘hits’? Gastroenterology. 114:842–845. 1998.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Kong W, Wei J, Abidi P, Lin M, Inaba S, Li
C, Wang Y, Wang Z, Si S, Pan H, et al: Berberine is a novel
cholesterol-lowering drug working through a unique mechanism
distinct from statins. Nat Med. 10:1344–1351. 2004.PubMed/NCBI View
Article : Google Scholar
|
|
30
|
Adams LA, Lymp JF, St Sauver J, Sanderson
SO, Lindor KD, Feldstein A and Angulo P: The natural history of
nonalcoholic fatty liver disease: A population-based cohort study.
Gastroenterology. 129:113–121. 2005.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Gibbons GF: Assembly and secretion of
hepatic very-low-density lipoprotein. Biochem J. 268:1–13.
1990.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Gibbons GF, Wiggins D, Brown AM and
Hebbachi AM: Synthesis and function of hepatic very-low-density
lipoprotein. Biochem Soc Trans. 32:59–64. 2004.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Rutledge AC, Su Q and Adeli K:
Apolipoprotein B100 biogenesis: A complex array of intracellular
mechanisms regulating folding, stability, and lipoprotein assembly.
Biochem Cell Biol. 88:251–267. 2010.PubMed/NCBI View
Article : Google Scholar
|
|
34
|
Fisher EA and Ginsberg HN: Complexity in
the secretory pathway: The assembly and secretion of apolipoprotein
B-containing lipoproteins. J Biol Chem. 277:17377–17380.
2002.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Olofsson SO, Stillemark-Billton P and Asp
L: Intracellular assembly of VLDL: Two major steps in separate cell
compartments. Trends Cardiovasc Med. 10:338–345. 2000.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Zhou M, Fisher EA and Ginsberg HN:
Regulated Co-translational ubiquitination of apolipoprotein B100. A
new paradigm for proteasomal degradation of a secretory protein. J
Biol Chem. 273:24649–24653. 1998.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Wang Y, Tran K and Yao Z: The activity of
microsomal triglyceride transfer protein is essential for
accumulation of triglyceride within microsomes in McA-RH7777 cells.
A unified model for the assembly of very low density lipoproteins.
J Biol Chem. 274:27793–27800. 1999.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Furbee JW Jr, Francone O and Parks JS: In
vivo contribution of LCAT to apolipoprotein B lipoprotein
cholesteryl esters in LDL receptor and apolipoprotein E knockout
mice. J Lipid Res. 43:428–437. 2002.PubMed/NCBI
|
|
39
|
Zou K, Li Z, Zhang Y, Zhang HY, Li B, Zhu
WL, Shi JY, Jia Q and Li YM: Advances in the study of berberine and
its derivatives: A focus on anti-inflammatory and anti-tumor
effects in the digestive system. Acta Pharmacol Sin. 38:157–167.
2017.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Yan YQ, Fu YJ, Wu S, Qin HQ, Zhen X, Song
BM, Weng YS, Wang PC, Chen XY and Jiang ZY: Anti-influenza activity
of berberine improves prognosis by reducing viral replication in
mice. Phytother Res. 32:2560–2567. 2018.PubMed/NCBI View
Article : Google Scholar
|
|
41
|
Warowicka A, Nawrot R and
Goździcka-Józefiak A: Antiviral activity of berberine. Arch Virol.
165:1935–1945. 2020.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Wu X, Li X, Dang Z and Jia Y: Berberine
demonstrates anti-inflammatory properties in Helicobacter
pylori-infected mice with chronic gastritis by attenuating the
Th17 response triggered by the B cell-activating factor. J Cell
Biochem. 119:5373–5381. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Li CL, Tan LH, Wang YF, Luo CD, Chen HB,
Lu Q, Li YC, Yang XB, Chen JN, Liu YH, et al: Comparison of
anti-inflammatory effects of berberine, and its natural oxidative
and reduced derivatives from Rhizoma Coptidis in vitro and in vivo.
Phytomedicine. 52:272–283. 2019.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Chao G, Ye F, Yuan Y and Zhang S:
Berberine ameliorates non-steroidal anti-inflammatory drugs-induced
intestinal injury by the repair of enteric nervous system. Fundam
Clin Pharmacol. 34:238–248. 2020.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Cicero AF and Baggioni A: Berberine and
its role in chronic disease. Adv Exp Med Biol. 928:27–45.
2016.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Wang K, Feng X, Chai L, Cao S and Qiu F:
The metabolism of berberine and its contribution to the
pharmacological effects. Drug Metab Rev. 49:139–157.
2017.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Zang M, Zuccollo A, Hou X, Nagata D, Walsh
K, Herscovitz H, Brecher P, Ruderman NB and Cohen RA: AMP-activated
protein kinase is required for the lipid-lowering effect of
metformin in insulin-resistant human HepG2 cells. J Biol Chem.
279:47898–47905. 2004.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Brusq J-M, Ancellin N, Grondin P, Guillard
R, Martin S, Saintillan Y and Issandou M: Inhibition of lipid
synthesis through activation of AMP kinase: An additional mechanism
for the hypolipidemic effects of berberine. J Lipid Res.
47:1281–1288. 2006.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Assifi MM, Suchankova G, Constant S,
Prentki M, Saha AK and Ruderman NB: AMP-activated protein kinase
and coordination of hepatic fatty acid metabolism of
starved/carbohydrate-refed rats. Am J Physiol Endocrinol Metab.
289:E794–E800. 2005.PubMed/NCBI View Article : Google Scholar
|
